Kevin Fischbeck

Q: What is Kevin Fischbeck's success rate?

Kevin Fischbeck currently has a success rate of 90.72881355932203.

Q: What is the average return of Kevin Fischbeck's calls?

Their stock ratings have generated an average return of 16.156335708772854.

B of A Securities | Healthcare

Kevin Fischbeck is an analyst from B of A Securities specializing in the Healthcare sector. Ranked #1904 out of 4635 analysts, they have issued 20 stock ratings with a success rate of 90.73% and an average return of 16.16%.

Kevin Fischbeck has a well-established track record, with 20 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 90.73% and an average return of 16.16%, underscoring their expertise and ability to identify winning opportunities for investors.

#1904

Out of 4635

Total Ratings

+90.73%

Success Rate

+16.16%

Average Return

Recent Ratings Analysis

ELV

Buy

Apr 29, 2026

Target

$435.00

Current

$362.74

Performance

—

Kevin Fischbeck rated ELV as Buy on Apr 29, 2026, setting a price target of 435. Shares have remained stable near 362.74, leaving the 435 target still in play.

CNC

Buy

Apr 29, 2026

Target

$60.00

Current

$49.57

Performance

—

On Apr 29, 2026, CNC was given a Buy rating by Kevin Fischbeck, with a target price of 60. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

OPCH

Buy

Dec 09, 2025

Target

$35.00

Current

$27.77

Performance

-13.81%

OPCH received a Buy rating from Kevin Fischbeck on Dec 09, 2025, aiming for 35. The rating hasn’t played out as hoped, with the stock trading 13.81% below expectations.

ACHC

Sell

Dec 03, 2025

Target

$21.50

Current

$27.58

Performance

87.75%

On Dec 03, 2025, Kevin Fischbeck published a Underperform outlook on ACHC, with a target of 21.5. Investors who followed the Sell rating avoided losses as the stock weakened.

ARDT

Sell

Nov 13, 2025

Target

$10.00

Current

$9.71

Performance

4.41%

Kevin Fischbeck on Nov 13, 2025 assigned ARDT a Underperform rating, with a price target of 10. The bearish stance awaits confirmation while shares hold level at 9.71.

HUM

Hold

Oct 10, 2025

Target

$300.00

Current

$229.72

Performance

-18.02%

On Oct 10, 2025, Kevin Fischbeck reaffirmed HUM with a Neutral rating, targeting 300. The Hold stance reflected market caution that was later justified.

UNH

Hold

Oct 08, 2025

Target

$390.00

Current

$366.77

Performance

-0.85%

UNH was rated Neutral by Kevin Fischbeck on Oct 08, 2025, with a price objective of 390. Flat performance suggests the Hold view was reasonable.

DVA

Sell

Sep 10, 2025

Target

$140.00

Current

$150.07

Performance

13.47%

On Sep 10, 2025, Kevin Fischbeck initiated coverage on DVA with a Underperform rating and target of 140. The rating correctly identified downside risks, with the stock losing 13.47%.

AMN

Sell

Sep 10, 2025

Target

$18.00

Current

$20.93

Performance

6.84%

Kevin Fischbeck issued a Underperform recommendation for AMN on Sep 10, 2025, price target set at 18. The bearish outlook played out, as shares fell from 20.93 to 20.93.

THC

Buy

Sep 10, 2025

Target

$225.00

Current

$177.50

Performance

-7.45%

On Sep 10, 2025, THC was evaluated by Kevin Fischbeck, who gave a Buy rating and target of 225. Investors saw limited payoff as shares fell short of the 225 target.

EHC

Buy

Sep 10, 2025

Target

$160.00

Current

$101.69

Performance

-18.39%

Kevin Fischbeck rated EHC as Buy on Sep 10, 2025, setting a price target of 160. The stock has underperformed, dropping 18.39% despite the bullish target of 160.

UHS

Sell

Jul 16, 2025

Target

$185.00

Current

$162.54

Performance

-4.55%

On Jul 16, 2025, UHS was given a Underperform rating by Kevin Fischbeck, with a target price of 185. The stock traded sideways with only a -4.55% move, leaving the Sell case unresolved.

HCA

Hold

Jul 16, 2025

Target

$410.00

Current

$431.92

Performance

19.12%

HCA received a Neutral rating from Kevin Fischbeck on Jul 16, 2025, aiming for 410. Investors saw gains of 19.12% that the cautious stance didn’t fully capture.

AGL

Sell

Oct 02, 2024

Target

$3.00

Current

$27.90

Performance

-68.83%

On Oct 02, 2024, Kevin Fischbeck published a Underperform outlook on AGL, with a target of 3. The Sell recommendation underestimated bullish momentum toward 3.

Frequency Asked Questions

Who is Kevin Fischbeck?

Kevin Fischbeck is an analyst from B of A Securities specializing in the Healthcare sector.

What is Kevin Fischbeck's success rate?

Kevin Fischbeck currently has a success rate of +90.73%.

How many ratings has Kevin Fischbeck issued?

Kevin Fischbeck has issued 20 stock ratings so far.

What is the average return of Kevin Fischbeck's calls?

Their stock ratings have generated an average return of +16.16%.

What is Kevin Fischbeck's ranking?

Kevin Fischbeck is ranked #1904 out of 4635 analysts.

What types of ratings does Kevin Fischbeck give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Kevin Fischbeck?

You can follow Kevin Fischbeck by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Kevin Fischbeck?

Their latest rating was a Buy on ELV issued on 2026-04-29.